Nuclea signs definitive deal for Moltex nuclear assets
Mangoceuticals merger partner Nuclea Energy signed a definitive deal to buy Moltex Energy’s advanced nuclear technology assets.
The asset purchase targets SSR-W molten salt reactor technology, the WATSS spent-fuel recycling process, related development materials, and an 80-patent portfolio.
The consideration is cash only, subject to adjustments tied to defined external debts; Moltex is in administration.
The portfolio reflects more than C$96 million of prior private investment and public funding; SSR-W completed Phase 1 of Canada’s CNSC vendor design review.
Closing is targeted within three months, subject to conditions including UK national security review and customary consents.
MGRX•
